MDP Stock Overview
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$2.90|
|52 Week High||CA$4.58|
|52 Week Low||CA$1.59|
|1 Month Change||58.47%|
|3 Month Change||10.69%|
|1 Year Change||11.11%|
|3 Year Change||-27.32%|
|5 Year Change||-35.56%|
|Change since IPO||-61.33%|
Recent News & Updates
|MDP||CA Pharmaceuticals||CA Market|
Return vs Industry: MDP exceeded the Canadian Pharmaceuticals industry which returned -61.8% over the past year.
Return vs Market: MDP exceeded the Canadian Market which returned 2.1% over the past year.
|MDP Average Weekly Movement||10.4%|
|Pharmaceuticals Industry Average Movement||13.6%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||18.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: MDP is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MDP's weekly volatility (10%) has been stable over the past year.
About the Company
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company’s primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication.
Medexus Pharmaceuticals Inc. Fundamentals Summary
|MDP fundamental statistics|
Is MDP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MDP income statement (TTM)|
|Cost of Revenue||US$32.79m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.12|
|Net Profit Margin||2.80%|
How did MDP perform over the long term?See historical performance and comparison